Peptide Therapeutics for Treating Ocular Surface Infections
نویسندگان
چکیده
منابع مشابه
Novel peptide therapeutics for treatment of infections.
As antibiotic resistance increases worldwide, there is an increasing pressure to develop novel classes of antimicrobial compounds to fight infectious disease. Peptide therapeutics represent a novel class of therapeutic agents. Some, such as cationic antimicrobial peptides and peptidoglycan recognition proteins, have been identified from studies of innate immune effector mechanisms, while others...
متن کاملMesenchymal stem cells for treating ocular surface diseases
Mesenchymal stem cells (MSC) have become a promising tool for cell therapy in regenerative medicine. They are readily available, demonstrate powerful differentiation capabilities and present immunosuppressive properties that aid them in surviving from host immune rejection for its great potential use in allograft. Currently clinical trials are underway using MSC, both culture-expanded allogenei...
متن کاملOcular Therapeutics
This book is of interest in so much as it describes the therapeutic methods and appliances in use in German ophthalmic practice at present. Looking through it the first and most striking point is the extent to which proprietary preparations are mentioned and used, thus under bismuth the use of only one pharmacopoeial preparation, the subnitrate, is mentioned, whereas seven proprietary ones are ...
متن کاملTreating ocular surface disease: new agents in development
This paper reviews recent advances and investigation in the treatment of ocular surface pathology. There is significant investment in this area, paralleling the growing demand for more effective alternatives to current treatments. Clinicians are becoming more aware of surface pathology, yet the ability to treat the most common forms of ocular pathology are still limited to the few medications a...
متن کاملHeteropolymers: a New Class of Therapeutics for Treating Lethal Bacterial and Viral Infections
Heteropolymers (HPs) contain a MAb directed against the Complement Receptor type 1 (CR1) on primate RBCs, chemically cross-linked to MAbs that recognize pathogens. Upon administration of HPs pathogens are bound to the HP and immobilized on RBCs, which move through the circulation to the liver and spleen where the CR1-HP-pathogen complex is phagocytosed and destroyed by tissue macrophages. A uni...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Ocular Pharmacology and Therapeutics
سال: 2014
ISSN: 1080-7683,1557-7732
DOI: 10.1089/jop.2014.0089